<DOC>
	<DOCNO>NCT02361424</DOCNO>
	<brief_summary>The purpose study assess safety efficacy cognitive impairment function several dos PXT00864 ( new fix combination acamprosate baclofen low dose ) patient mild Alzheimer Disease .</brief_summary>
	<brief_title>Pilot Study Assessing Effects PXT00864 Patients With Mild Alzheimer Disease ( AD )</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Acamprosate</mesh_term>
	<criteria>Male female patient age ≥ 60 year . Patient diagnosis probable AD Progressive decline cognition six month story document patient medical record A MiniMental State Examination ( MMSE ) score 2026 With minimum educational background Naïve antidementia treatment MRI assessment corroborate clinical diagnosis ( hippocampal atrophy ) exclude potential cause dementia especially cerebrovascular lesion If available , Cerebral Spinal Fluid ( CSF ) classical biomarkers level corroborate clinical diagnosis Ambulatory patient living home caregiver available living household interact patient daily available necessary ensure administration investigational product Absence major severe depressive disease Patient willingness participate study sign informed consent form Early onset dementia , i.e . 60 year old avoid hereditary AD form Significant neurological disease AD Major psychiatric disorder syndrome ( schizophrenia bipolar disorder ) Seizure disorder Other infectious , metabolic systemic disease affect central nervous system Other active clinically significant illness Hospitalization change chronic concomitant medication one month prior screen Patients severe respiratory , hepatic renal failure significantly potentially disable abnormality detect screen Known hypersensitivity test treatment include active substance excipients . Patients participate another study expose investigational therapy within 30 day prior entry study . Patient without medical care insurance</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>PXT00864</keyword>
	<keyword>mild AD</keyword>
	<keyword>phase 2a</keyword>
</DOC>